(From AFX Europe (Focus))
LONDON (AFX) - Belgium's UCB SA and US-based Biogen Idec said they will collaborate to jointly develop and market CDP323 for the treatment of multiple sclerosis.
CDP323 is a small molecule inhibitor expected to enter Phase II clinical trials next year.
UCB will receive upfront and additional payments for development and commercial milestones in excess of 200 mln usd. Biogen Idec will contribute to …